Detalles de la búsqueda
1.
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Lancet
; 395(10240): 1845-1854, 2020 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32450106
2.
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet
; 396(10249): 479-488, 2020 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32702299
3.
Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial.
Emerg Microbes Infect
; 13(1): 2281355, 2024 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37933089
4.
Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre study.
Lancet Respir Med
; 11(8): 698-708, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37209700
5.
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.
Lancet Respir Med
; 11(7): 613-623, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36898400
Resultados
1 -
5
de 5
1
Próxima >
>>